FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Frank Dougherty

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Erythropoiesis

Co-author Network

Publications

TOP 3
Simon D Roger; Prajej Ruangkanchanasetr; Sheldon W Tobe; Rainer P Woitas; Kwan-Dun Wu; Ulrich Beyer; Thomas A Golper; Agnes Ladanyi; Maurice Laville; Ho Yung Lee; Francesco Locatelli; Alberto Martínez-Castelao; Michal Nowicki; Robert Provenzano; Frank C Dougherty
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
Iain C Macdougall; Rowan Walker; Robert Provenzano; Fernando de Alvaro; Harold R Locay; Paul C Nader; Francesco Locatelli; Frank C Dougherty; Ulrich Beyer
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
Marian Klinger; Manual Arias; Vassilis Vargemezis; Anatole Besarab; Wladyslaw Sulowicz; Trevor Gerntholtz; Kazimierz Ciechanowski; Frank C Dougherty; Ulrich Beyer
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Frank Dougherty (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Simon D Roger; Prajej Ruangkanchanasetr; Sheldon W Tobe; Rainer P Woitas; Kwan-Dun Wu; Ulrich Beyer; Thomas A Golper; Agnes Ladanyi; Maurice Laville; Ho Yung Lee; Francesco Locatelli; Alberto Martínez-Castelao; Michal Nowicki; Robert Provenzano; Frank C Dougherty
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(12):3980-6.
2008: Iain C Macdougall; Rowan Walker; Robert Provenzano; Fernando de Alvaro; Harold R Locay; Paul C Nader; Francesco Locatelli; Frank C Dougherty; Ulrich Beyer
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
Clinical journal of the American Society of Nephrology : CJASN 2008;3(2):337-47.
2007: Marian Klinger; Manual Arias; Vassilis Vargemezis; Anatole Besarab; Wladyslaw Sulowicz; Trevor Gerntholtz; Kazimierz Ciechanowski; Frank C Dougherty; Ulrich Beyer
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2007;50(6):989-1000.
2007: Anne Pannier; Paul Jordan; Frank C Dougherty; Fabrice Bour; Bruno Reigner
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
Current medical research and opinion 2007;23(12):3025-32.
2007: Steven Fishbane; Anne Pannier; Xavier Liogier; Paul Jordan; Frank C Dougherty; Bruno Reigner
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
Journal of clinical pharmacology 2007;47(11):1390-7.
2007: R Provenzano; Anatole Besarab; Iain C Macdougall; David H Ellison; A P Maxwell; W Sulowicz; Marian Klinger; B Rutkowski; R Correa-Rotter; Frank C Dougherty
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Clinical nephrology 2007;67(5):306-17.
2007: Francesco Locatelli; Giuseppe Villa; A L M de Francisco; Alberto Albertazzi; Horacio J Adrogue; Frank C Dougherty; Ulrich Beyer
Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.
Current medical research and opinion 2007;23(5):969-79.
2007: Anatole Besarab; Moro O Salifu; N Martin Lunde; Vinod Bansal; Steven Fishbane; Frank C Dougherty; Ulrich Beyer
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Clinical therapeutics 2007;29(4):626-39.
2006: A L M de Francisco; W Sulowicz; M Klinger; S Niemczyk; Vassilis Vargemezis; F Metivier; Frank C Dougherty; D Oguey
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
International journal of clinical practice 2006;60(12):1687-96.
2006: Iain C Macdougall; Richard Robson; Sylvie Opatrna; Xavier Liogier; Anne Pannier; Paul Jordan; Frank C Dougherty; Bruno Reigner
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
Clinical journal of the American Society of Nephrology : CJASN 2006;1(6):1211-5.